GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Gross-Profit-to-Asset %

PCI Biotech Holding ASA (FRA:4QG) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. PCI Biotech Holding ASA's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.00 Mil. PCI Biotech Holding ASA's average Total Assets over the quarter that ended in Dec. 2024 was €2.97 Mil. Therefore, PCI Biotech Holding ASA's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

PCI Biotech Holding ASA Gross-Profit-to-Asset % Historical Data

The historical data trend for PCI Biotech Holding ASA's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Gross-Profit-to-Asset % Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PCI Biotech Holding ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PCI Biotech Holding ASA's Gross-Profit-to-Asset %

For the Biotechnology subindustry, PCI Biotech Holding ASA's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Gross-Profit-to-Asset % falls into.


;
;

PCI Biotech Holding ASA Gross-Profit-to-Asset % Calculation

PCI Biotech Holding ASA's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0/( (3.829+2.657)/ 2 )
=0/3.243
=0.00 %

PCI Biotech Holding ASA's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (3.274+2.657)/ 2 )
=0/2.9655
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

PCI Biotech Holding ASA Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
OSL:CRNA OSL:BGBIO OSL:ABTEC OSL:ABS OSL:ONCIN OSL:EXTX OSL:SOFTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170
Traded in Other Exchanges
PCIB:Norway 0JGL:UK
Address
Ullernchausseen 64, Oslo, NOR, N-0379
Website
https://www.pcibiotech.com
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines